How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, sex, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance consultation

Closed for comments This consultation ended on at   Request commenting lead permission

1 Recommendations

1.1

Ruxolitinib is not recommended, within its marketing authorisation, for treating non-segmental vitiligo with facial involvement in people 12 years and over.

1.2

This recommendation is not intended to affect treatment with ruxolitinib that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop. For children or young people, this decision should be made jointly by the clinician, the child or young person, and their parents or carers.

Why the committee made these recommendations

There are no licensed treatments for non-segmental vitiligo. Initial treatment may include topical corticosteroids and topical calcineurin inhibitors which are used on the skin. After trying these, some people have phototherapy.

Clinical trial evidence shows that ruxolitinib increases repigmentation and reduces how noticeable the vitiligo patches are compared with a type of cream called 'vehicle cream' (which is equivalent to not having any treatment because it does not contain an active ingredient). It is uncertain how well ruxolitinib works compared with phototherapy because the company provided no evidence to support this comparison.

The assumptions in the company's economic model do not reflect how vitiligo is treated in clinical practice. It was not possible to determine a reliable cost-effectiveness estimate. So, ruxolitinib is not recommended.